Characteristics of Treatment Cycles (n = 216)
| . | Group A (n = 110; platelet trigger 10 × 109/L) . | Group B (n = 106; platelet trigger 20 × 109/L) . | P Value . |
|---|---|---|---|
| Induction I/II v consolidation I/II | 51/33 v17/9 | 46/29 v 19/12 | NS |
| Complete remission rate | 52% | 68% | .09 |
| Platelet count before each cycle: </>100 × 109/L | 64/46 | 41/65 | <.05 |
| Median duration of thrombocytopenia (<25 × 109/L) in days | 18 (1-113) | 13 (0-56) | <.05 |
| Platelet transfusions: | |||
| Apheresis/pooled concentrates | 1/5.13 | 1/5.28 | NS |
| Platelets leukoreduced by filtration | 87% | 95% | NS |
| . | Group A (n = 110; platelet trigger 10 × 109/L) . | Group B (n = 106; platelet trigger 20 × 109/L) . | P Value . |
|---|---|---|---|
| Induction I/II v consolidation I/II | 51/33 v17/9 | 46/29 v 19/12 | NS |
| Complete remission rate | 52% | 68% | .09 |
| Platelet count before each cycle: </>100 × 109/L | 64/46 | 41/65 | <.05 |
| Median duration of thrombocytopenia (<25 × 109/L) in days | 18 (1-113) | 13 (0-56) | <.05 |
| Platelet transfusions: | |||
| Apheresis/pooled concentrates | 1/5.13 | 1/5.28 | NS |
| Platelets leukoreduced by filtration | 87% | 95% | NS |
Abbreviation: NS, not significant.